Track topics on Twitter Track topics that are important to you
MONTREAL, June 6, 2017 /PRNewswire/ -- Novatek International has been selected by Boehringer Ingelheim as their approved Vendor and Partner for a worldwide solution for Environmental Monitoring Software. Boehringer Ingelheim plans to implement and validate the NOVA-EM (Environmental Monitoring) solution at multiple sites worldwide.
After considering the time and cost of customizing and configuring their current LIMS and ERP systems to make a customized solution for environmental monitoring (EM), Boehringer Ingelheim decided to go with a dedicated solution for their EM needs.
NOVA-EM from Novatek International was chosen as the global standard by Boehringer Ingelheim following a thorough RFP process, involving several vendors, and evaluation of the available LIMS and EM solutions.
NOVA-EM is Novatek's Solution dedicated to managing all aspects of an automated Environmental Monitoring Program. NOVA-EM is a business ready, process specific "off the shelf" (OTS) solution that meets 95+ percent of environmental monitoring automaton requirements out of the box. As a GAMP 5 category 3 software system, implementing NOVA-EM equates rapid installation, implementation, validation, and deployment. The time and cost savings, in contrast to configurable systems, is undeniable and a key reason for the selection of the NOVA-EM solution.
Novatek's modular approach combined with a globally proven deployment process, provides Boehringer Ingelheim a clear and concise roadmap to plan and add additional off the shelf, process specific modules such as Cleaning Validation Management (NOVA-CVM) to create a larger solution for complete contamination control.
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
About Novatek International
Established in 1996, NOVATEK's mission is dedicated to help pharmaceutical companies and other life science organizations leverage their investment in information technology and quality processes by reducing cost, improving productivity and enhancing compliance. With 20 years of user experience and developer level technical support, simple or complex installations are seamless and rapid. The architecture of all NOVATEK solutions are out of the box, modular and process-based, enabling the applications to be delivered "business-ready" providing the building blocks for a complete quality solution.
Nissa Barkat, Marketing Manager
1-514-668-2835 ext 3604
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/novatek-international-selected-as-partner-for-automation-of-boehringer-ingelheims-global-environmental-monitoring-program-300469215.html
SOURCE Novatek InternationalNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...